Compare
PepGen Inc. vs Gossamer Bio, Inc. vs Corbus Pharmaceuticals Holdings, Inc. vs Climb Bio, Inc.
| Latest fiscal year | PepGen Inc. PEPG | Gossamer Bio, Inc. GOSS | Corbus Pharmaceuticals Holdings, Inc. CRBP | Climb Bio, Inc. CLYM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $48.47M | n/a | n/a |
| Revenue growth (YoY) | n/a | -57.7% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -352.2% | n/a | n/a |
| Net margin | n/a | -351.5% | n/a | n/a |
| Net income | -$89.66M | -$170.37M | -$78.54M | -$59.85M |
| EPS (Diluted) | -$2.12 | -$0.75 | -$5.90 | -$0.88 |
| Operating cash flow | -$81.64M | -$171.27M | -$64.49M | -$54.36M |
| Free cash flow | -$81.90M | -$171.34M | -$64.50M | -$54.54M |
| Cash & equivalents | $60.51M | $37.73M | $28.49M | $35.69M |
| Total assets | $173.91M | $172.25M | $168.19M | $167.74M |
| Total liabilities | $26.46M | $295.01M | $20.69M | $7.27M |
| Shareholders' equity | $147.44M | -$122.76M | $147.50M | $160.47M |
| Return on year-end equity | -60.8% | n/a | -53.2% | -37.3% |
| Shares outstanding | 68.87M | 233.68M | 17.61M | 47.77M |
Revenue, most recent five fiscal years
| Fiscal year | PepGen Inc. | Gossamer Bio, Inc. | Corbus Pharmaceuticals Holdings, Inc. | Climb Bio, Inc. |
|---|---|---|---|---|
| Latest | n/a | $48.47M Ended 2025-12-31 | $0 Ended 2022-12-31 | n/a |
| 1 year earlier | n/a | $114.70M Ended 2024-12-31 | $881.7K Ended 2021-12-31 | n/a |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $3.94M Ended 2020-12-31 | n/a |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | $36.14M Ended 2019-12-31 | n/a |
| 4 years earlier | n/a | n/a | $4.82M Ended 2018-12-31 | n/a |